Wallac Oy

Pharmacia Ab

Opko Diagnostics, LLC

Abacus Diagnostica Oy

Timo Lovgren

Ilkka Hemmila

Vincent Linder

David Steinmiller

Marek Kwiatkowski

Jan P Carlsson

Kim Pettersson

Peter T Scardino

Hans Lilja

Andrew J Vickers

Jussi Nurmi

Erkki J Soini

Sven O Oscarsson

Hakan Drevin

Anna T Martin

Jukka Lavi

Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.

Compositions and methods related to diagnosis of prostate cancer

A reagent container having an inner surface upon which at least two reagents are dried, with the first reagent dried on a first area separate from a second area where the second reagent is dried. The first and second reagents are a nucleic acid polymerase and its substrate. A method is disclosed which includes dispensing at least the first and second reagents onto separate areas of the inner surface of the reagent container, and removing excess water from the reagents. The reagent container can be used in a polymerase chain reaction (PCR) assay, an assay that utilizes a reverse transcriptase, a reverse transcriptase polymerase chain reaction, an immuno-PCR assay, a nucleic acid sequence based assay, a proximity ligation assay, a ligase chain reaction assay, a rolling circle amplification assay, and a strand displacement amplification assay.

Method for stabilizing assay reagents, reagent container with stabilized assay reagents and use thereof

Method for a homogeneous biospecific affinity assay for determining the content of a substance (analyte) in a biological sample. The assay is carried out in an aqueous reaction medium by means of time-resolved fluorescence spectroscopy and with a biospecific affinity reactant labeled with a lanthanide chelate in which a lanthanide ion exhibiting ionic fluorescence is chelated by a ligand bound covalently to the reactant. The characteristic feature is

Modulated homogeneous fluorescence biospecific affinity assay employing

Enzyme activity determinations method characterized by the using of

Method for quantitative determination of a biospecific affinity reaction in which an immunochemical compound labelled with a lanthanide chelate is used which can be detected by means of time-resolved fluorescence in which the amount of labelled compound present in the biospecific affinity reaction can be measured without the separation of free and biospecifically bound labelled compound having to be carried out.

Method for quantitative determination of a biospecific affinity reaction

A method for determining NADH and/or NADPH-concentrations, for instance in NADH- or NADPH transforming systems, the method comprising the step of bringing the sample subject to determination in contact with the bioluminescent reagent based on bacteria luciferase, NAD(P)H-FMN oxidoreductase, FMN and aliphatic aldehyde, whereby a reaction takes place, where NAD(P)H is oxidized and FMN is reduced, the reaction being catalyzed by the oxidoreductase, whereafter the FMNH.sub.2 formed and the aldehyde are bound to the luciferase and light is emitted, the intensity of this light being measured and constituting a measure of the NADH- or NADPH-concentration, whereby in the determination a bacteria luciferase purified so as not to obtain any oxidoreductase is used in combination with a predetermined amount of oxidoreductase, this amount being such that a stable light intensity is obtained in the presence of a constant amount of NADH or NADPH whereby an internal calibration can be carried out in NADH or NADPH transforming systems by adding a predetermined amount of NADH or NADPH followed by a subsequent measuring of the increase of the light intensity.

Bioluminescence method for determining NADH or NADPH

Growing community of inventors

Turku, Finland

Timo Lovgren